Search:

Filter:

Post type:

Sort:

He just wanted to get back to work: a simple backache ended in tragedy

August 17, 2026

35-year-old Tyreek Lewis just wanted his back pain to stop, but pain relief would mean time off from work, hours of tests, and extra appointments. So he took what looked like a simple shortcut. It killed him, and altered his family’s life forever.

Judgment, USA v Anise Kachadourian

August 14, 2026

United States District Court District of New Jersey USA v Anise Kachadourian Judgment Filed May 2026 Read the document.

Plea Agreement, USA v Anise Kachadourian

August 14, 2026

United States District Court District of New Jersey USA v Anise Kachadourian Plea Agreement Filed May 2023 Read the document.

Information, USA v Anise Kachadourian

August 14, 2026

United States District CourtDistrict of New Jersey USA v Anise Kachadourian Information Filed May 2023 Read the document.

Plea Agreement, USA v Jon Paul Dadaian

August 14, 2026

United States District Court District of New Jersey USA v Jon Paul Dadaian Plea Agreement Filed May 2022 Read the document.

Information, USA v Jon Paul Dadaian

August 14, 2026

United States District Court District of New Jersey USA v Jon Paul Dadaian Information Filed May 2022 Read the document.

Judgment, USA v Joel Lerner

August 14, 2026

United States District Court District of New Jersey USA v Joel Lerner Judgment Filed June 2026 Read the document.

Plea Agreement, USA v Joel Lerner

August 14, 2026

United States District Court District of New Jersey USA v Joel Lerner Plea Agreement Filed February 2023 Read the document.

Information, USA v Joel Lerner

August 14, 2026

United States District Court District of New Jersey USA v Joel Lerner Information Filed February 2023 Read the document.

Mass drug compounding risks

August 14, 2026

How does mass compounding threaten patients? Drug compounding is intended to meet individual patient needs or temporarily bridge shortages – but the GLP-1 market has broken that model. Today, telehealth companies and compounding entities are mass-producing and marketing unapproved compounded GLP-1s. These unapproved versions put patient health and informed decision-making at risk because they are produced outside the FDA’s rigorous…